Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT Pharmaceuticals's gross profit for the
six
months ended in Mar. 2026 was €0.13 Mil. China SXT Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21 Mil.
China SXT Pharmaceuticals (FRA:2RY2) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
China SXT Pharmaceuticals had a gross margin of 28.73% for the quarter that ended in Mar. 2026 => Competition eroding margins
China SXT Pharmaceuticals Gross Profit Related Terms
China SXT Pharmaceuticals Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2RY2 vs CBIH, UPC, NPHC: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.21 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
China SXT Pharmaceuticals (FRA:2RY2) has a Gross Profit of €0.21 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on China SXT Pharmaceuticals and its competitors.
Is China SXT Pharmaceuticals' Gross Profit too high?
China SXT Pharmaceuticals' current Gross Profit is €0.21 Mil. Overall, China SXT Pharmaceuticals has a GF Score™ of 19/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Gross Profit compare to CBIH and UPC?
China SXT Pharmaceuticals' Gross Profit of €0.21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on China SXT Pharmaceuticals and its competitors. China SXT Pharmaceuticals's current Gross Profit is €0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (FRA:2RY2) is currently considered Possible Value Trap. The stock's GF Value™ is €5.74, compared to a current price of €3.04 — trading 47.1% below its estimated fair value. The current Gross Profit is €0.21 Mil. China SXT Pharmaceuticals' overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY2), the current Gross Profit is €0.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (FRA:2RY2) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €3.04 is trading 47.1% below its estimated GF Value™ of €5.74.
GuruFocus considers China SXT Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:2RY2:
Gross Profit: €0.21 Mil
GF Value™: €5.74 vs. price of €3.04 (47.1% below fair value)
No single metric tells the full story. See the FRA:2RY2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
19GF Score
Get the complete analysis for FRA:2RY2
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY2 has been successfully added to your 
